Phase II Trial of Irinotecan, Carboplatin, and Bevacizumab in the Treatment of Patients with Extensive-Stage Small-Cell Lung Cancer

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Journal of Thoracic Oncology

• Publication date

  2009-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/JTO.0b013e3181bbc540PMID 19875975
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Phase II trial of irinotecan and carboplatin for extensive or relapsed small-cell lung cancer.

  2009cited by this paper
• S0124: A randomized phase III trial comparing irinotecan/cisplatin (IP) with etoposide/cisplatin (EP) in patients (pts) with previously untreated extensive stage small cell lung cancer (E-SCLC)

  2008cited by this paper
• Irinotecan plus carboplatin versus oral etoposide plus carboplatin in extensive small-cell lung cancer: a randomized phase III trial.

  2008cited by this paper
• A phase II study of cisplatin (P) plus etoposide (E) plus bevacizumab (B) for previously untreated extensive stage small cell lung cancer (SCLC) (E3501): A trial of the Eastern Cooperative Oncology Group

  2007cited by this paper
• CALGB 30306: A phase II study of cisplatin (C), irinotecan (I) and bevacizumab (B) for untreated extensive stage small cell lung cancer (ES-SCLC)

  2007cited by this paper
• Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer.

  2007cited by this paper
• Irinotecan, Carboplatin, and Imatinib in Untreated Extensive-Stage Small-Cell Lung Cancer: A Phase II Trial of the Minnie Pearl Cancer Research Network

  2007cited by this paper
• Phase II study of vandetanib or placebo in small-cell lung cancer patients after complete or partial response to induction chemotherapy with or without radiation therapy: National Cancer Institute of Canada Clinical Trials Group Study BR.20.

  2007cited by this paper
• Phase III double-blind, placebo-controlled study of thalidomide in extensive-disease small-cell lung cancer after response to chemotherapy: an intergroup study FNCLCC cleo04 IFCT 00-01.

  2007cited by this paper
• A randomized phase II trial of irinotecan plus carboplatin versus etoposide plus carboplatin treatment in patients with extended disease small-cell lung cancer.

  2006cited by this paper
• Phase II study of irinotecan combined with carboplatin in previously untreated small-cell lung cancer

  2006cited by this paper
• Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database.

  2006cited by this paper
• Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.

  2006cited by this paper
• Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer.

  2006cited by this paper
• Open-label, multicenter, randomized, phase III study comparing oral topotecan/cisplatin versus etoposide/cisplatin as treatment for chemotherapy-naive patients with extensive-disease small-cell lung cancer.

  2006cited by this paper
• Irinotecan (I), carboplatin (C), and radiotherapy (RT) followed by maintenance bevacizumab (B) in the treatment (tx) of limited-stage small cell lung cancer (LS-SCLC): Update of a phase II trial of the Minnie Pearl Cancer Research Network.

  2006cited by this paper
• Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

  2004cited by this paper
• Evolving role of irinotecan in small-cell lung cancer.

  2003cited by this paper
• Evolving role of irinotecan in small-cell lung cancer.

  2003cited by this paper
• Phase II study of irinotecan and carboplatin in patients with the refractory or relapsed small cell lung cancer.

  2003cited by this paper
• A high vascular count and overexpression of vascular endothelial growth factor are associated with unfavourable prognosis in operated small cell lung carcinoma

  2002cited by this paper
• Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer.

  2002cited by this paper
• Serum vascular endothelial growth factor levels correlate better with tumour stage in small cell lung cancer than albumin, neuron‐specific enolase or lactate dehydrogenase

  2002cited by this paper
• Relationship between vessel density and expression of vascular endothelial growth factor and basic fibroblast growth factor in small cell lung cancer in vivo and in vitro.

  2000cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors

  2000cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

  2000cited by this paper
• Carboplatin dosage: prospective evaluation of a simple formula based on renal function.

  1989cited by this paper
• Nonparametric Estimation from Incomplete Observations

  1958cited by this paper

• Amphotericin-A21 Induces Antineoplastic Effects through the Modulation of Apoptosis in Human Tumoral Cells

  2025cites this paper
• Dopamine D2 receptor agonists abrogate neuroendocrine tumour angiogenesis to inhibit chemotherapy-refractory small cell lung cancer progression

  2024cites this paper
• Chemotherapy combined with bevacizumab for small cell lung cancer with brain metastases: A case report

  2024cites this paper
• Targeted Therapies in Small Cell Lung Cancer: From Old Failures to Novel Therapeutic Strategies

  2023cites this paper
• Novel Therapeutic Options for Small Cell Lung Cancer

  2023cites this paper
• Effectiveness and safety of bevacizumab in extensive-disease small cell lung cancer: a systemic review and meta-analysis

  2021influential citation
• Small Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology.

  2021cites this paper
• Combination therapy: Future directions of immunotherapy in small cell lung cancer

  2020cites this paper
• A narrative review of salvage therapy in small cell lung cancer

  2020cites this paper
• Inhibition of Tumor Angiogenesis in the Treatment of Lung Cancer

  2019cites this paper
• Anti-angiogenesis treatment in a patient with appendix metastasis of small cell lung cancer

  2019cites this paper
• Apatinib for chemotherapy-refractory extensive-stage SCLC: a retrospective study

  2019cites this paper
• pH-Mediated molecular differentiation for fluorimetric quantification of chemotherapeutic drugs in human plasma.

  2018cites this paper
• Advanced small cell lung cancer (SCLC): new challenges and new expectations.

  2018cites this paper
• Structural and photodynamic properties of the anti-cancer drug irinotecan in aqueous solutions of different pHs.

  2018cites this paper
• Genetic Mutations and Humanized Monoclonal Antibody Treatment in Small-Cell Lung Cancer: A Review

  2017cites this paper
• Small Cell Lung Cancer and Molecular Targeted Therapy

  2017cites this paper
• Randomized Phase II Trial of Cisplatin and Etoposide in Combination With Veliparib or Placebo for Extensive-Stage Small-Cell Lung Cancer: ECOG-ACRIN 2511 Study.

  2017cites this paper
• Bevacizumab in extensive-disease small cell lung cancer: the search continues

  2017cites this paper
• Progress and challenges in the treatment of small cell lung cancer

  2017cites this paper
• A randomized, double‐blind, phase 2 trial of platinum therapy plus etoposide with or without concurrent vandetanib (ZD6474) in patients with previously untreated extensive‐stage small cell lung cancer: Hoosier Cancer Research Network LUN06‐113

  2017cites this paper
• Italian, Multicenter, Phase III, Randomized Study of Cisplatin Plus Etoposide With or Without Bevacizumab as First-Line Treatment in Extensive-Disease Small-Cell Lung Cancer: The GOIRC-AIFA FARM6PMFJM Trial.

  2017cites this paper
• Meta-analysis of the role of bevacizumab in extensive stage small cell lung cancer

  2017cites this paper
• Small-Cell Lung Cancer: Clinical Management and Unmet Needs New Perspectives for an Old Problem.

  2017cites this paper
• Elusive Target of Angiogenesis in Small-Cell Lung Cancer.

  2017cites this paper
• Research progress in the treatment of small cell lung cancer

  2017influential citation
• Advances in antiangiogenic treatment of small-cell lung cancer

  2017cites this paper
• Targeting angiogenesis in small cell lung cancer.

  2016cites this paper
• Targeted drugs in small-cell lung cancer.

  2016cites this paper
• Phase II study of bevacizumab plus irinotecan on the treatment of relapsed resistant small cell lung cancer

  2016cites this paper
• Efficacy and safety of angiogenesis inhibitors in small-cell lung cancer

  2016cites this paper
• Place des antiangiogéniques dans le traitement des cancers du poumon

  2016cites this paper
• Development of molecularly targeted agents and immunotherapies in small cell lung cancer.

  2016influential citation
• Is there a Place for Bevacizumab in Patients with Extensive-Stage Small Cell Lung Cancer?

  2016cites this paper
• Genomic profiling of small-cell lung cancer: the era of targeted therapies.

  2015cites this paper
• Current status of CPT and its analogues in the treatment of malignancies

  2015influential citation
• Italian multicenter phase III randomized study of cisplatin-etoposide with or without bevacizumab as first-line treatment in extensive stage small cell lung cancer: treatment rationale and protocol design of the GOIRC-AIFA FARM6PMFJM trial.

  2015influential citation
• Small Cell Lung Cancer: Will Recent Progress Lead to Improved Outcomes?

  2015cites this paper
• Cisplatin, Etoposide, and Bevacizumab Regimen Followed by Oral Etoposide and Bevacizumab Maintenance Treatment in Patients With Extensive-Stage Small Cell Lung Cancer: A Single-Institution Experience.

  2015influential citation
• Targeted therapies for small cell lung cancer: Where do we stand?

  2015cites this paper
• Small cell lung cancer: therapies and targets.

  2014cites this paper
• To combine or not combine: the role of radiotherapy and targeted agents in the treatment for renal cell carcinoma

  2014cites this paper
• Treatment of small cell lung cancer.

  2014cites this paper
• Phase II trial of Sorafenib in conjunction with chemotherapy and as maintenance therapy in extensive-stage small cell lung cancer

  2014cites this paper
• Combination of intravitreal bevacizumab and systemic therapy for choroidal metastases from lung cancer: report of two cases and a systematic review of literature

  2014cites this paper
• Southwest Oncology Group S0802: a randomized, phase II trial of weekly topotecan with and without ziv-aflibercept in patients with platinum-treated small-cell lung cancer.

  2014cites this paper
• NCCN Guidelines Version 1.2015 Panel Members Non-Small Cell Lung Cancer

  2014cites this paper
• NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines

  2014cites this paper
• Advances in Lung Cancer and Treatment Research

  2013cites this paper
• The development of targeted therapy in small cell lung cancer.

  2013cites this paper
• Efficacy and safety of oral topotecan and bevacizumab combination as second-line treatment for relapsed small-cell lung cancer: an open-label multicenter single-arm phase II study.

  2013cites this paper
• Rationale for Chemotherapy, Immunotherapy, and Checkpoint Blockade in SCLC: Beyond Traditional Treatment Approaches

  2013cites this paper
• Medical treatment of small cell lung cancer: state of the art and new development

  2013cites this paper
• Carboplatin and paclitaxel plus ASA404 as first-line chemotherapy for extensive-stage small-cell lung cancer: a multicenter single arm phase II trial (SAKK 15/08).

  2013cites this paper
• [Bevacizumab in thoracic oncology: results and practical aspects].

  2013cites this paper
• Treatment of Small Cell Lung Cancer Diagnosis and Management of Lung Cancer , 3 rd ed : American College of Chest Physicians Evidence-Based Clinical Practice Guidelines

  2013cites this paper
• Small cell lung cancer.

  2013cites this paper
• Treatment of Small Cell Lung Cancer Diagnosis and Management of Lung Cancer , 3 rd ed : American College of Chest Physicians Evidence-Based Clinical Practice Guidelines

  2013cites this paper
• NCCN Small Cell Lung Cancer Clinical Practice Guidelines in Oncology

  2013cites this paper
• Phase II study of maintenance sunitinib following irinotecan and carboplatin as first-line treatment for patients with extensive-stage small-cell lung cancer.

  2012cites this paper
• Treatment of small cell lung cancer

  2012cites this paper
• Treatment Update in Small-Cell Lung Cancer: From Limited to Extensive Disease

  2012cites this paper
• Emerging drugs for small cell lung cancer – an update

  2012cites this paper
• Aggregation properties and structural studies of anticancer drug Irinotecan in DMSO solution based on NMR measurements

  2012cites this paper
• Systemic issues in small cell lung cancer.

  2012cites this paper
• Anti‐VEGF antibody therapy does not promote metastasis in genetically engineered mouse tumour models

  2012cites this paper
• Les antiangiogéniques : limites actuelles en oncologie thoracique

  2012cites this paper
• Targeted therapies in small cell lung cancer.

  2012cites this paper
• [Targeted agents in the treatment of lung cancer].

  2012cites this paper
• Small Cell Lung Cancer: Lung Neuroendocrine Tumors: NCCN Small Cell Lung Cancer Panel Members Initial Evaluation and Staging (SCL-1)

  2012cites this paper
• Primary treatment and prognostic factors of small cell neuroendocrine carcinoma of the uterine cervix: a Taiwanese Gynecologic Oncology Group study.

  2012cites this paper
• Chemotherapy for small cell lung cancer: a comprehensive review

  2012cites this paper
• Paclitaxel plus bevacizumab in patients with chemoresistant relapsed small cell lung cancer as salvage treatment: a phase II multicenter study of the Hellenic Oncology Research Group.

  2012cites this paper
• [Antiangiogenic agents: current limits in thoracic oncology].

  2012cites this paper
• Targeted Therapy in Lung Cancer: Lessons Learned from Past Experiences

  2011cites this paper
• Organ-specific carboxylesterase profiling identifies the small intestine and kidney as major contributors of activation of the anticancer prodrug CPT-11.

  2011cites this paper
• Small cell lung cancer.

  2011cites this paper
• Irinotecan plus carboplatin in patients with extensive-disease small-cell lung cancer

  2011cites this paper
• Emerging treatments for small-cell lung cancer: Phase II and III trials

  2011cites this paper
• Angiogenesis and Lung Cancer

  2011cites this paper
• Current management of small cell lung cancer.

  2011cites this paper
• Small Cell Lung CancerPractice Guidelines in Oncology

  2011cites this paper
• Phase II study of cisplatin/etoposide and endostar for extensive-stage small-cell lung cancer

  2011cites this paper
• Cibler aussi le mésothéliome pleural malin et le cancer bronchique à petites cellules

  2011cites this paper
• Randomized phase II study of bevacizumab in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer: results from the SALUTE trial.

  2011cites this paper
• Small cell lung cancer.

  2011cites this paper
• Small cell lung cancer: new clinical recommendations and current status of biomarker assessment.

  2011cites this paper
• Mesothelioma and small cell lung cancer.

  2011cites this paper
• Chemotherapy-Induced Weakness and Fatigue in Skeletal Muscle: The Role of Oxidative Stress

  2011cites this paper
• The molecular pathogenesis of small cell lung cancer

  2010cites this paper
• Paclitaxel Plus Bevacizumab in Patients with Chemosensitive Relapsed Small Cell Lung Cancer: A Safety, Feasibility, and Efficacy Study from the Hoosier Oncology Group

  2010cites this paper
• 小细胞肺癌的的分子发病机制

  2010cites this paper
• Sorafenib in Platinum-Treated Patients with Extensive Stage Small Cell Lung Cancer: A Southwest Oncology Group (SWOG 0435) Phase II Trial

  2010cites this paper
• Phase II study of cisplatin plus etoposide and bevacizumab for previously untreated, extensive-stage small-cell lung cancer: Eastern Cooperative Oncology Group Study E3501.

  2009cites this paper
• Novel systemic therapies for small cell lung cancer.

  2008cites this paper
• Targeting Angiogenesis in the Treatment of Lung Cancer

  2008cites this paper
• Management of Small Cell Lung Cancer

  2005cites this paper
• ystemic Agents in Chemotherapy-Naive SCLC Irinotecan

  year unknowncites this paper